JNJ-41443532 |
| Catalog No.GC70720 |
JNJ-41443532 (antagonista CCR2 5) es un inhibiselectivo de hCCR2 activo por vía oral con buena afinde Unión (IC50=37 nM) y potente antagonismo funcional (quimiotaxis IC50=30 nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1228650-83-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
JNJ-41443532 (compound 8d) dose-dependently inhibits the influx of leukocytes, monocytes/macrophages and T-lymphocytes into the peritoneal cavity with an ED50 of 3 mg/kg p.o. bid in a thioglycollate-induced peritonitis (TG) model[1].
JNJ-41443532 has good CV safety profile. It does not induce dose-dependent or notable effects on most cardiohemodynamic, functional respiratory and electrophysiological parameters up to 10 mg/kg (i.v.) with plasma level at 70 µM in an anesthetized dog[1].
JNJ-41443532 has amendable oral bioavailability in dogs and primates. Pharmacokinetic parameters (p.o.)[1]:
| Species | Dose (mg/kg) | Cmax (ng/mL) | AUClast (h*ng/mL) | Oral bioavailability (%) |
| dogs | 6.7 | 1617 | 5887 | 70.2 |
| non-human primates | 7.2 | 740 | 3061 | 25.4 |
| mice | 10 | 74 | 204 | 19 |
| rats | 10 | 100 | 416 | 15.3 |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *